Literature DB >> 26088570

HLA-DQ genetic risk gradient for type 1 diabetes and celiac disease in northwestern Mexico.

M E Mejía-León1, K M Ruiz-Dyck1, A M Calderón de la Barca2.   

Abstract

BACKGROUND: Type 1 diabetes (T1D) and celiac disease (CD) are the 2 most common autoimmune childhood diseases that share their HLA-DQ2 and DQ8 genetic origin. There has currently been an increase in both diseases worldwide. In children from the low-population State of Sonora (15 inhabitants/km(2)) in north-western Mexico, there is no information on their genetic risk or the distribution of the related alleles in the general population. AIMS: To compare the HLA-DQ allele frequency in a representative sample of newborns from Sonora with that of T1D and CD patients to determine the risk gradient, and to identify the presence of celiac autoimmunity in the T1D group.
METHODS: The study included 397 Sonoran newborns, with 44 cases of T1D, and 25 CD cases. The CD and T1D cases were clinically diagnosed by specialists at the Hospital Infantil del Estado de Sonora, and the autoantibodies were determined by ELISA. Whole blood was collected, gDNA was extracted, and HLA-DQ2 and DQ8 were typed by PCR-SSP. The risk gradient was calculated by comparing the allele frequencies of the cases with those of the newborns.
RESULTS: The Sonoran HLA-DQ risk heterodimer proportion was 16.1% for HLA-DQ2 and 13.6% for HLA-DQ8, with an HLA-DQ2:HLA-DQ8 ratio of 1.2:1. The DQ8/DQ2 genotype represented a 1:14 risk for T1D, whereas the DQ8/DQB1*0201 combination showed a 1:6 risk for CD. The prevalence of CD autoimmunity in T1D children was 7%.
CONCLUSION: The Sonoran population has a distinctive HLA-DQ allele distribution due to its ancestry. The HLA-DQ8 combinations with DQ2 or one of its alleles conferred the highest risk for both diseases, and T1D and CD frequently appear together.
Copyright © 2015 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. All rights reserved.

Entities:  

Keywords:  Celiac disease; Diabetes tipo 1; Enfermedad celíaca; HLA-DQ2; HLA-DQ8; Mexico; México; Type 1 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26088570     DOI: 10.1016/j.rgmx.2015.03.003

Source DB:  PubMed          Journal:  Rev Gastroenterol Mex        ISSN: 0375-0906


  6 in total

1.  HLA-DQ: Celiac disease vs inflammatory bowel disease.

Authors:  Marta Maia Bosca-Watts; Miguel Minguez; Dolores Planelles; Samuel Navarro; Alejandro Rodriguez; Jesus Santiago; Joan Tosca; Francisco Mora
Journal:  World J Gastroenterol       Date:  2018-01-07       Impact factor: 5.742

2.  Carrier frequency of HLA-DQB1*02 allele in patients affected with celiac disease: A systematic review assessing the potential rationale of a targeted allelic genotyping as a first-line screening.

Authors:  Dimitri Poddighe; Chiara Rebuffi; Annalisa De Silvestri; Cristina Capittini
Journal:  World J Gastroenterol       Date:  2020-03-28       Impact factor: 5.742

3.  Prevalence of haplotype DQ2/DQ8 and celiac disease in children with type 1 diabetes.

Authors:  Agnieszka Zubkiewicz-Kucharska; Tatiana Jamer; Joanna Chrzanowska; Katarzyna Akutko; Tomasz Pytrus; Andrzej Stawarski; Anna Noczyńska
Journal:  Diabetol Metab Syndr       Date:  2022-09-12       Impact factor: 5.395

4.  The distribution of HLA DQ2 and DQ8 haplotypes and their association with health indicators in a general Danish population.

Authors:  Line Lund Kårhus; Betina H Thuesen; Tea Skaaby; Jüri J Rumessen; Allan Linneberg
Journal:  United European Gastroenterol J       Date:  2018-03-08       Impact factor: 4.623

Review 5.  Diet, Microbiota and Immune System in Type 1 Diabetes Development and Evolution.

Authors:  María E Mejía-León; Ana M Calderón de la Barca
Journal:  Nutrients       Date:  2015-11-06       Impact factor: 5.717

6.  Frequency of HLA-DQ, susceptibility genotypes for celiac disease, in Brazilian newborns.

Authors:  Fernanda C Almeida; Lenora Gandolfi; Karina N Costa; Marilucia R A Picanço; Lucas M Almeida; Yanna K M Nóbrega; Riccardo Pratesi; Claudia B Pratesi; Nicole Selleski
Journal:  Mol Genet Genomic Med       Date:  2018-07-16       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.